Figure 3

IP₃R_ant administered ICV reversed IP₃’s effect (a) and enhanced Li’s effect in the FST (b). (a, b) Immobility time in the FST 45 min following ICV administration of 10 pmol of IP₃R_ant in liposomes. (a) Two-way ANOVA: *IP₃ treatment: F(1,62)=7.98, P<0.01; IP₃R_ant treatment: F(1,62)=1.78, P=0.18; *IP₃ treatment × IP₃R_ant treatment interaction: F(1,62)=4.11, P=0.046; Fisher’s LSD post hoc analysis: *IP₃ vs aCSF, P<0.01; *IP₃+IP₃R_ant vs IP₃, P=0.02. (b) Two-way ANOVA: *Li treatment: F(1,59)=27.03, P<0.01; *IP₃R_ant treatment: F(1,59)=4.7, P=0.03; Li treatment × IP₃R_ant treatment interaction: F(1,59)=0.83, P=0.3; Fisher’s LSD post hoc analysis: *Li+aCSF vs regular food+aCSF, P<0.01; *Li+IP₃R_ant vs Li+aCSF, P=0.04. aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; FST, forced swim test; ICV, intracerebroventricularly; IP, inositol phosphate; IP₃R_ant, IP₃ receptor antagonist.